Table 2

Peak plasma PZA concentrations achieved at MTD as reported in Phase I clinical trials

Dose (mg/m2)SchedulePeak plasma level (μm)AUC (μm·h)Ref. no.
6001-h i.v. every 3 wks2.17 ± 1.0530 ± 25 10
7503-h i.v. every 3 wks2.3 (range, 1.4–4.5) 12
1501-h i.v. × 5 days every 3 wksDay 1 2.5 (range, 0.7–11.3) 12
Days 2–5 5.6 (range, 2.6–9.5)
28124-h i.v. every 3 or 4 wks1.656 11